Houston Methodist is researching the effect of virtual reality on cancer patients. Photo courtesy of Houston Methodist

Virtual reality goes far beyond playing games with titles like Arizona Sunshine, Moss, Robo Recall, and Tetris Effect. VR also is playing an ever-growing role in health care settings. The global market for VR in health care could reach $3.8 billion in 2020, according to one estimate.

VR is touching all corners of heath, including robotic surgeries, training, pain management, and behavior modification, according to InterbrandHealth, a health care branding agency. And these technologies are happening right here in Houston.

Researchers at Houston Methodist Cancer Center are exploring whether exposure to nature, through either a real garden or VR, can ease pain and distress in cancer patients who are undergoing chemotherapy. This approach might decrease the need for prescription painkillers.

Houston Methodist and Texas A&M University are leading this test. Renee Stubbins, a clinical dietitian at Houston Methodist Cancer Center, and Ashley Verzwyvelt, an infusion oncology nurse at the cancer center, proposed the research after several years of studying ways that nature can boost the healing process.

"Anything that affects our patients' comfort — including easing pain and anxiety, and possibly reducing the need for pain medications — is important to their recovery," Stubbins says in a release. "People have an innate connection to nature, and we hope the patients will respond positively."

Three dozen cancer patients receiving chemotherapy infusions every two weeks during at least six cycles will be randomly assigned to one of three rooms: a live-garden-view room; a window-less room, and a room where nature can be experienced through a VR headset.

Teaming up with Houston-based Skyline Art Services, local artist Gonzo247 produced a nature-inspired mural on a wall behind the live garden to create an immersive environment. The mural depicts a flowering garden, blue sky and sunset that enhance the live garden of Texas wildflowers in the foreground.

Researchers will measure pain, distress, blood pressure, heart rate, and saliva cortisol at the beginning and end of each infusion visit. Saliva cortisol, a hormone produced when the body is stressed, helps gauge a patient's condition.

"If this study proves that real or virtual elements of nature help the healing process, then it has potential to positively impact our patients," Verzwyvelt says. "Some of them are hesitant to take pain medication due to concerns of addiction and adverse side effects, so I'm excited to see the possibilities this kind of research could bring."

Houston Methodist Cancer Center says the VR experiment could have implications for treatment of an array of patients who are immobile or whose immune systems are compromised.

"We looked at multiple studies that showed exposure to nature can reduce stress levels and actually increase productivity and creativity," says Ann McNamara, associate professor in the Department of Visualization at Texas A&M. "We want to see if we can reproduce those effects in a natural environment in virtual reality."

The study is being financed by the Center for Health & Nature, a joint initiative of Houston Methodist, Texas A&M and Texan by Nature, a nonprofit conservation group founded by former first lady Laura Bush. The Center for Health & Nature, housed at Houston Methodist Hospital, debuted in 2018.

"There's a gap in research regarding what nature factors lead to increased health, what exposure to nature means, and how much exposure is needed," Bush said when the center was announced.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston edtech company closes oversubscribed $3M seed round

fresh funding

Houston-based edtech company TrueLeap Inc. closed an oversubscribed seed round last month.

The $3.3 million round was led by Joe Swinbank Family Limited Partnership, a venture capital firm based in Houston. Gamper Ventures, another Houston firm, also participated with additional strategic partners.

TrueLeap reports that the funding will support the large-scale rollout of its "edge AI, integrated learning systems and last-mile broadband across underserved communities."

“The last mile is where most digital transformation efforts break down,” Sandip Bordoloi, CEO and president of TrueLeap, said in a news release. “TrueLeap was built to operate where bandwidth is limited, power is unreliable, and institutions need real systems—not pilots. This round allows us to scale infrastructure that actually works on the ground.”

True Leap works to address the digital divide in education through its AI-powered education, workforce systems and digital services that are designed for underserved and low-connectivity communities.

The company has created infrastructure in Africa, India and rural America. Just this week, it announced an agreement with the City of Kinshasa in the Democratic Republic of Congo to deploy a digital twin platform for its public education system that will allow provincial leaders to manage enrollment, staffing, infrastructure and performance with live data.

“What sets TrueLeap apart is their infrastructure mindset,” Joe Swinbank, General Partner at Joe Swinbank Family Limited Partnership, added in the news release. “They are building the physical and digital rails that allow entire ecosystems to function. The convergence of edge compute, connectivity, and services makes this a compelling global infrastructure opportunity.”

TrueLeap was founded by Bordoloi and Sunny Zhang and developed out of Born Global Ventures, a Houston venture studio focused on advancing immigrant-founded technology. It closed an oversubscribed pre-seed in 2024.

Texas space co. takes giant step toward lunar excavator deployment

Out of this world

Lunar exploration and development are currently hampered by the fact that the moon is largely devoid of necessary infrastructure, like spaceports. Such amenities need to be constructed remotely by autonomous vehicles, and making effective devices that can survive the harsh lunar surface long enough to complete construction projects is daunting.

Enter San Antonio-based Astroport Space Technologies. Founded in San Antonio in 2020, the company has become a major part of building plans beyond Earth, via its prototype excavator, and in early February, it completed an important field test of its new lunar excavator.

The new excavator is designed to function with California-based Astrolab's Flexible Logistics and Exploration (FLEX) rover, a highly modular vehicle that will perform a variety of functions on the surface of the moon.

In a recent demo, the Astroport prototype excavator successfully integrated with FLEX and proceeded to dig in a simulated lunar surface. The excavator collected an average of 207 lbs (94kg) of regolith (lunar surface dust) in just 3.5 minutes. It will need that speed to move the estimated 3,723 tons (3,378 tonnes) of regolith needed for a lunar spaceport.

After the successful test, both Astroport and Astrolab expressed confidence that the excavator was ready for deployment. "Leading with this successful excavator demo proves that our technology is no longer theoretical—it is operational," said Sam Ximenes, CEO of Astroport.

"This is the first of many implements in development that will turn Astrolab's FLEX rover into the 'Swiss Army Knife' of lunar construction. To meet the infrastructure needs of the emerging lunar economy, we must build the 'Port' before the 'Ship' arrives. By leveraging the FLEX platform, we are providing the Space Force, NASA, and commercial partners with a 'Shovel-Ready' construction capability to secure the lunar high ground."

"We are excited to provide the mobility backbone for Astroport's groundbreaking construction technology," said Jaret Matthews, CEO of Astrolab, in a release. "Astrolab is dedicated to establishing a viable lunar ecosystem. By combining our FLEX rover's versatility with Astroport's civil engineering expertise, we are delivering the essential capabilities required for a sustainable lunar economy."

---

This article originally appeared on CultureMap.com.

Houston biotech co. raises $11M to advance ALS drug development

drug money

Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.

India-based pharmaceuticals company Dr. Reddy’s Laboratories Inc. led the round with a $10 million investment, according to a news release. New York-based investment firm Greenlight Capital, Coya’s largest institutional shareholder, contributed $1.1 million.

The funding was raised through a definitive securities purchase agreement for the purchase and sale of more than 2.5 million shares of Coya's common stock in a private placement at $4.40 per share.

Coya reports that it plans to use the proceeds to scale up manufacturing of low-dose interleukin-2 (IL-2), which is a component of its COYA 302 and will support the commercial readiness of the drug. COYA 302 enhances anti-inflammatory T cell function and suppresses harmful immune activity for treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease.

The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026.

Coya was founded in 2021. The company merged with Nicoya Health Inc. in 2020 and raised $10 million in its series A the same year. It closed its IPO in January 2023 for more than $15 million. Its therapeutics uses innovative work from Houston Methodist's Dr. Stanley H. Appel.